drugset / Trial / NCT04443907

Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)

NCT04443907 ↗

Phase 1 Terminated 4 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study evaluated a genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) product - OTQ923 to reduce the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle cell disease.

Timeline

Start
2020-08-25
Primary completion
2025-01-06
Completion
2025-01-06

Outcome

Outcome not reported

Stopped (Business): “The decision of early termination was made due to business reasons and was not a consequence of any safety concern.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject OTQ923 Unknown — Intravenous

Indications